Open AccessThis article is
- freely available
Endocannabinoids and Schizophrenia
Centre de Recherche Fernand-Seguin, Department of Psychiatry, University of Montreal, 7331 Hochelaga, Montreal, Quebec, H1N 3V2, Canada
* Author to whom correspondence should be addressed.
Received: 10 September 2010; Accepted: 25 September 2010 / Published: 8 October 2010
Abstract: The endocannabinoids anandamide and 2-arachydonoylglycerol (2-AG) are lipids naturally derived from membrane precursors which bind cannabinoid receptors (CB1, CB2). This endocannabinoid system is disturbed in schizophrenia. Indeed, there seems to be an association between schizophrenia and polymorphisms of the CB1 receptor gene. Moreover, CB1 receptors are found in higher density in the prefrontal cortex, hippocampus and basal ganglia of patients with schizophrenia. Similarly, anandamide levels are increased in the cerebrospinal fluid (CSF) and in the serum of schizophrenia patients, including during the prodromal state, suggesting that they may play a protective role in psychosis homeostasis. Future studies are needed to further explore the role of the endocannabinoid system in the pathophysiology of schizophrenia.
Keywords: endocannabinoids; schizophrenia; cannabis; drug abuse; metabolism
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Desfossés, J.; Stip, E.; Bentaleb, L.A.; Potvin, S. Endocannabinoids and Schizophrenia. Pharmaceuticals 2010, 3, 3101-3126.
Desfossés J, Stip E, Bentaleb LA, Potvin S. Endocannabinoids and Schizophrenia. Pharmaceuticals. 2010; 3(10):3101-3126.
Desfossés, Joëlle; Stip, Emmanuel; Bentaleb, Lahcen Ait; Potvin, Stéphane. 2010. "Endocannabinoids and Schizophrenia." Pharmaceuticals 3, no. 10: 3101-3126.